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Abstract
Background: Accumulation of profibrotic myofibroblasts in fibroblastic foci (FF) is a crucial process for development of
fibrosis during idiopathic pulmonary fibrosis (IPF) pathogenesis, and transforming growth factor (TGF)-β plays a key
regulatory role in myofibroblast differentiation. Reactive oxygen species (ROS) has been proposed to be involved in the
mechanism for TGF-β-induced myofibroblast differentiation. Metformin is a biguanide antidiabetic medication and its
pharmacological action is mediated through the activation of AMP-activated protein kinase (AMPK), which regulates not
only energy homeostasis but also stress responses, including ROS. Therefore, we sought to investigate the inhibitory role
of metformin in lung fibrosis development via modulating TGF-β signaling.
Methods: TGF-β-induced myofibroblast differentiation in lung fibroblasts (LF) was used for in vitro models. The anti-
fibrotic role of metfromin was examined in a bleomycin (BLM)-induced lung fibrosis model.
Results: We found that TGF-β-induced myofibroblast differentiation was clearly inhibited by metformin treatment in
LF. Metformin-mediated activation of AMPK was responsible for inhibiting TGF-β-induced NOX4 expression. NOX4
knockdown and N-acetylcysteine (NAC) treatment illustrated that NOX4-derived ROS generation was critical for TGF-β-
induced SMAD phosphorylation and myofibroblast differentiation. BLM treatment induced development of lung
fibrosis with concomitantly enhanced NOX4 expression and SMAD phosphorylation, which was efficiently inhibited by
metformin. Increased NOX4 expression levels were also observed in FF of IPF lungs and LF isolated from IPF patients.
Conclusions: These findings suggest that metformin can be a promising anti-fibrotic modality of treatment for IPF
affected by TGF-β.
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Background
Accumulation of profibrotic myofibroblasts is a crucial
process for fibrotic remodeling in idiopathic pulmonary fi-
brosis (IPF) [1]. Among a variety of profibrotic cytokines,
transforming growth factor (TGF)-β has been widely impli-
cated in IPF pathogenesis through regulating myofibroblast
differentiation and proliferation [1]. Adenoviral transfer of
TGF-β1 to rat lung induces prolonged severe interstitial fi-
brosis characterized by extensive deposition of extracellular
matrix (ECM) proteins and accumulation of cells with a
myofibroblast phenotype [2]. Integrin αvβ6-mediated
physiological activation of TGF-β has been demonstrated
to be involved in lung fibrosis development at least partly
through epithelial-mesenchymal transition [3, 4]. With re-
spect to a clinical implication, the concentrations of TGF-
β1 in the bronchoalveolar lavage fluid (BALF) from IPF
cases were significantly higher than those from control
cases [5]. Hence, TGF-β is thought to play a crucial role in
orchestrating fibrosis development during IPF pathogenesis
and recent ongoing clinical trials have mainly focused on
inhibition of fibrotic mechanisms, including TGF-β [6].
TGF-β-mediated biological activities are regulated via
intracellular signaling pathways composed of canonical
SMADs and SMAD-independent non-canonical path-
ways, including mitogen activated protein (MAP) kinases
and phosphoinositide 3-kinase (PI3K) [7]. Reactive oxy-
gen species (ROS) modulate TGF-β-induced cell signal-
ing pathways via activating tyrosine kinases and
inactivating protein tyrosine phosphatases, and NADPH
oxidases (NOXes) are the major source of endogenous
ROS production [8]. Among seven isoforms of NOXes,
NOX4 has been shown to modulate TGF-β/SMAD-sig-
naling via intracellular ROS production [8]. In compari-
son to other isoforms, NOX4 is unique in that it is
constitutively active, thus its expression level is a major
point of regulation [9]. Increased expression levels of
NOX4 have been reported in IPF lung, including in
myofibroblasts in fibroblastic foci (FF), suggesting the
involvement of NOX4 in IPF pathogenesis through
modulating TGF-β-induced myofibroblast differentiation
[10, 11]. Recent papers also demonstrated potential
therapeutic implications for a low-molecular weight
NOX4 antagonist in prevention of bleomycin (BLM)-in-
duced lung fibrosis [12]. Accordingly, NOX4 has been
recognized to be a potential therapeutic target for IPF
associated with enhanced TGF-β signaling.
Metformin is a commonly prescribed biguanide antidi-
abetic medication used to lower blood glucose in type II
diabetes patients and also exhibits pleiotropic effects on
cellular biology [13]. Metformin has been shown to re-
duce TGF-β-induced ECM protein production in fibro-
blasts derived from nasal polyps [14]. Furthermore,
metformin prevented airway remodeling in mouse
models of bronchial asthma, suggesting a potential anti-
fibrotic property [15]. Accordingly, recent papers have
demonstrated metformin-mediated attenuation of bleo-
mycin (BLM) and gefitinib-induced lung fibrosis through
regulation of TGF-β signaling [16]. Pharmacological ac-
tion of metformin is mediated via the phosphorylation
of AMP-activated protein kinase (AMPK) [17], and
AMPK regulates not only intracellular energy balance
via lipid and glucose metabolism but also a wide array of
cell functions [18]. AMPK activation by metformin was
responsible for inhibiting TGF-β-induced collagen pro-
duction in mouse renal fibroblasts [19]. Furthermore,
AMPK has been demonstrated to negatively regulate
NOX4 expression in glomerular epithelial cells [20]. We
therefore examined the inhibitory mechanisms of met-
formin in TGF-β-induced myofibroblast differentiation
of lung fibroblasts (LF), and also evaluated the anti-
fibrotic role of metformin by using bleomycin (BLM)-in-
duced lung fibrosis mouse models in relation to AMPK
activation and NOX4 suppression.
Methods
Cell culture, antibodies, and reagents
Normal lung tissues were obtained from pneumonec-
tomy and lobectomy specimens from primary lung can-
cer. Informed consent was obtained from all surgical
participants as part of an approved ongoing research
protocol by the ethical committee of Jikei University
School of Medicine {#20-153 (5443)}. Lung fibroblasts
(LF) were isolated and characterized as previously de-
scribed [21]. Briefly, LF outgrown from lung fragments
were cultured in fibroblast growth media (DMEM with
10 % FCS and penicillin-streptomycin). LF were serially
passaged and used for experiments until passage 6. LF
demonstrated >95 % positive staining with anti-vimentin
antibodies, and <5 % positive staining with the anti-
cytokeratin antibody (Data not shown). Antibodies used
were rabbit anti-AMPKα (Cell Signaling Technology, #
2532), rabbit anti-phospho-AMPKα (T172) (Cell Signal-
ing Technology, # 2535), rabbit anti-NOX4 (Novus, #
NB110-58849), goat anti-type I collagen (Southern Bio-
tech, # 1310-01), mouse anti-α smooth muscle actin
(Sigma-Aldrich, # A2547), rabbit anti-SMAD2 (Cell Sig-
naling Technology, # 3122), rabbit anti-SMAD3 (Cell
Signaling Technology, # 9513), rabbit anti-phospho-
SMAD2 (Cell Signaling Technology, # 3101), rabbit anti-
phospho-SMAD3 (Cell Signaling Technology, # 8769),
rabbit anti- phospho-SMAD3 (phospho S423 + S425)
(Abcam, # 52903), and mouse anti-β-actin (Sigma-Aldrich,
# A5316). Metformin was provided from Sumitomo
Dainippon Pharma Co, Tokyo, Japan. Recombinant human
TGF-β1 (R&D Systems, # 100-B), N-acetylcysteine (NAC)
(Wako, # 017-05131), CM-H2DCFDA (Life Technologies,
# C6827), and bleomycin (Nippon Kayaku Co., Tokyo,
Japan) were purchased.
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siRNA and transfection
Small interfering RNA (siRNA) targeting AMPK (Applied
Biosystems Life Technologies, # 4392420, ID:S100 and
S102), NOX4 (QIAGEN, Hs_NOX4_6 FlexiTube siRNA, #
SI02642507 and Applied Biosystems Life Technologies, #
4392420, ID:27013), and negative control siRNAs (Applied
Biosystems Life Technologies, # AM4635 and # AM4641)
were purchased. Specific knockdowns of AMPK, and
NOX4 were validated using two different siRNA, respect-
ively. Transfections of LF were performed using the Neon®
Transfection System (Invitrogen Life Technologies, #
MPK5000), using matched optimized transfection kits
(Invitrogen Life Technologies, # MPK10096).
RNA isolation, polymerase chain reaction
RNA isolation, reverse transcription and Real-Time PCR
were performed using the SYBR green method as previ-
ously described [21]. The primers used were NOX4 sense
primer, 5’- CAGATGTTGGGGCTAGGATTG -3’; NOX4
antisense primer, 5’- GAGTGTTCGGCACATGGGTA
-3’; β-actin sense primer 5’-CATGTACGTTGCTATCC
AGGC -3’ β-actin antisense primer 5’-CTCCTTAATGT
CACGCACGAT -3’. These primer sets yielded PCR prod-
ucts of 96 bp and 250 bp for NOX4 and β-actin respect-
ively. Primer sequences were from Primer Bank (http://
pga.mgh.harvard.edu/primerbank.)
Measurement of ROS production
LF, at a density of 5 × 103 per well, were seeded in a 96-
well microplate (Thermo Fisher Scientific, # 237105).
CM-H2DCFDA was used to measure total cellular ROS
according to the manufacturer’s instructions. After
incubation with CM-H2DCFDA (10 μM) for 30 min at
37 °C, fluorescence of DCF was measured at an excita-
tion wavelength of 485 nm and an emission wavelength
of 535 nm by a fluorescence microplate reader (Infinite
F 200) (Tecan Japan, Kanagawa, Japan).
Western blotting
LF grown on 6-well culture plates were lysed in RIPA
buffer (Thermo Fisher Scientific, catalog # 89900)
with protease inhibitor cocktail (Roche Diagnostics, #
11697498001) and 1 mM sodium orthovanadate, or
lysed with Laemmli sample buffer. Western blotting
was performed as previously described [21, 22]. For
each experiment, equal amounts of total protein were
resolved by 7.5‐10 % SDS/PAGE. After SDS/PAGE,
proteins were transferred to polyvinylidene difluoride
(PVDF) membrane (Millipore, # ISEQ00010), and in-
cubation with specific primary antibody was per-
formed for 1 h at 37 °C, or 24 h at 4 °C. After
washing several times with PBST, the membrane was
incubated with Anti-rabbit IgG, HRP-linked secondary
antibody (Cell Signaling Technology, # 7074), Anti-
mouse IgG, HRP-linked secondary antibody, # 7076)
or Anti-goat IgG (H + I), HRP-linked secondary anti-
body (BETHYL, #A50-100P) followed by chemilumin-
escence detection (Thermo scientific, # 34080, and
BIO-RAD, # 1705061) with the LAS-4000 UVmini
system (Fujifilm, Tokyo, Japan) and ChemiDocTM
Touch Imaging System (BIO-RAD, California, USA).
Mouse models
C57BL/6J mice were purchased (CLEA Japan INC,
Tokyo, Japan) and were maintained in the animal
facility at the Jikei University School of Medicine. All
experimental procedures are approved by the Jikei
University School of Medicine Animal Care Commit-
tee (#25031). A dose of 3 U/kg bleomycin (Nippon
Kayaku Co., Tokyo, Japan) was intratracheally admin-
istered in 50 μL saline using MicroSprayer™ Aerosoli-
zer and a high pressure syringe (PennCentury,
Philadelphia, PA). Intraperitoneal dose of metformin
(300 mg/kg) were given from day 7 to day 20. On the
21th day the lungs were removed. The lungs were
fixed overnight in 10 % buffered formalin, embedded
in paraffin, and the sections are stained with
hematoxylin & eosin (HE).
Masson’s trichrome staining and immunohistochemistry
To evaluate the changes of collagen deposition in lungs,
Masson’s trichrome staining was performed as previ-
ously described [22]. Immunohistochemical staining was
performed as previously described with minor modifica-
tions on the paraffin-embedded lung tissues [21, 22]. N-
Histofine MOUSESTAIN KIT (Nichirei Biosciences Inc.,
# 414321) was used for immunohistochemical staining
of mouse lung sections.
Sircol soluble collagen assay
For quantitatively measuring collagen in mouse left
lungs, the Sircol soluble collagen assay was performed
according to the manufacturer’s instructions (Biocolor
Life Science Assay, # S100).
Statistics
Data are shown as the average (±SEM) taken from at
least three independent experiments. Student’s t-test was
used for comparison of two data sets, analysis of vari-
ance for multiple data sets. Tukey’s or Dunn’s test were
used for parametric and nonparametric data, respect-
ively, to find where the difference lay. Significance was
defined as p < 0.05. Statistical software used was Prism
v.5 (GraphPad Software, Inc., San Diego, CA).
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Results
Metformin inhibits TGF-β-induced myofibroblast differen-
tiation via AMPK activation in LF
TGF-β induced myofibroblast differentiation is shown by
an increase in type I collagen and αSMA expression levels
in LF (Fig. 1a, b, c). Metformin suppressed myofibroblast
differentiation in a dose dependent manner and significant
reduction was observed at concentrations of 10 mM
(Fig. 1a). Hence, a metformin concentration of 10 mM
was chosen for further analysis of cell culturing models.
The pharmacological action of metformin is mainly medi-
ated through activation of AMPK [17]. Metformin-
induced AMPK activation was confirmed by detecting the
phosphorylated form of AMPK with concomitant sup-
pression of αSMA expression levels (Fig. 1b).
To elucidate the involvement of AMPK activation in
regulation of myofibroblast differentiation by metformin,
we employed siRNA-mediated AMPK knockdown.
AMPK knockdown clearly reduced the amount of phos-
phorylation of AMPK following metformin treatment. In
line with recent findings [16], inhibition of myofibroblast
differentiation by metformin was clearly abrogated by
AMPK knockdown, indicating that AMPK activation is
involved in this inhibition (Fig. 1c).
Fig. 1 Metformin inhibits myofibroblast differentiation through AMPK activation in LF. a Western blotting (WB) using anti-type I collagen, anti-α-
smooth muscle actin (SMA), and anti-β-actin of cell lysates from control (lane 1, 2), metformin (1 mM) (lane 3, 4), and metformin (10 mM) (lane 5,
6) treated LF. Metformin treatment was started 1 h before TGF-β (2 ng/ml) stimulation and protein samples were collected after 24 h treatment
with TGF-β. In the right panels are the average (±SEM) taken from three independent experiments shown as relative expression. Open bar is
control and filled bar is TGF-β treated. *p < 0.05. b WB using anti-phospho-AMPK, anti-αSMA, and anti-β-actin of cell lysates from control (lane 1,
2) and metformin (10 mM) (lane 3, 4) treated LF. Metformin treatment was started 1 h before TGF-β (2 ng/ml) stimulation and protein samples
were collected after 24 h treatment with TGF-β. In the right panels are the average (±SEM) taken from three independent experiments shown as
relative expression. Open bar is control and filled bar is TGF-β treated. *p < 0.05. c WB using anti-type I collagen, anti-αSMA, anti-phospho-AMPK,
and anti-β-actin of cell lysates from control siRNA (lane 1, 2, 3, 4) and AMPK siRNA (lane 5, 6, 7, 8) transfected LF. Metformin treatment was started
48 h post transfection and 1 h before TGF-β (2 ng/ml) stimulation. Protein samples were collected after 24 h treatment with TGF-β. The right
panels show the average (±SEM) of type I collagen and αSMA relative expression, which were taken from five to six independent experiments,
respectively. Open bar is control and filled bar is TGF-β treated. *p < 0.05
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NOX4 is involved in metformin-mediated inhibition of
myofibroblast differentiation in LF
Recent papers demonstrated a pivotal role for NOX4 in
TGF-β signaling and myofibroblast differentiation [11].
To elucidate the participation of NOX4 in metformin-
mediated regulation of myofibroblast differentiation, the
changes in NOX4 expression levels following TGF-β
treatment were evaluated in the presence or absence of
metformin. TGF-β significantly enhanced NOX4 expres-
sion at the protein level, which was significantly sup-
pressed by metformin (Fig. 2a). TGF-β also increased
NOX4 expression at the mRNA level, which peaked at
12 hr post-treatment (Fig. 2b left panel). Metformin
treatment subsequently showed efficient inhibition of
TGF-β-induced NOX4 mRNA (Fig. 2b right panel).
NOX4 siRNA was employed and efficient knockdown
was confirmed by western blotting (Fig. 2c). TGF-β-in-
duced myofibroblast differentiation was clearly inhibited
by NOX4 knockdown (Fig. 2c). To confirm the association
between AMPK and NOX4, the changes of expression
levels of NOX4 following metformin treatment were ex-
amined in the setting of AMPK knockdown. Metformin-
Fig. 2 Metformin-mediated AMPK activation is involved in suppression of TGF-β-induced NOX4 expression in LF. a WB using anti-NOX4, and anti-
β-actin of cell lysates from control (lane 1, 2) and metformin (lane 3, 4) treated LF. Metformin treatment was started 1 h before TGF-β (2 ng/ml)
stimulation and protein samples were collected after 24 h treatment with TGF-β. Lower panel is the average (±SEM) taken from three independent
experiments shown as relative expression. Open bar is control and filled bar is metformin treated. *p < 0.05. b Left panel: LF were treated with TGF-β
and mRNA samples were collected at indicated time points (n = 9). *p < 0.05. Right panel: LF were treated with TGF-β in the presence or absence of
metformin (10 mM) and mRNA samples were collected after 12 h treatment with TGF-β (n = 6). Open bar is control and filled bar is metformin treated.
Real time-PCR was performed using primers to NOX4 or β-actin, as a control. NOX4 expression was normalized to β-actin. Shown is the fold increase
(±SEM) relative to control treated cells. *p < 0.05. c WB using anti-NOX4, anti-type I collagen, anti-α-smooth muscle actin (SMA) and anti-β-actin of cell
lysates from control siRNA (lane 1, 2) and NOX4 siRNA (lane 3, 4) transfected LF. TGF-β (2 ng/ml) treatment was started 48 h post transfection. Protein
samples were collected after 24 h treatment with TGF-β. In the right panels are the average (±SEM) taken from four independent experiments shown
as relative expression. Open bar is control and filled bar is TGF-β treated. *p < 0.05. d WB using anti-phospho-AMPK, anti-NOX4, anti-type I collagen,
anti-αSMA, and anti-β-actin of cell lysates from control siRNA (lane 1, 2, 3, 4) and AMPK siRNA (lane 5, 6) transfected LF. Metformin treatment was
started 48 h post transfection and 1 h before TGF-β (2 ng/ml) stimulation, and protein samples were collected after 24 h treatment with TGF-β. In the
right panels are the average (±SEM) taken from five independent experiments shown as relative expression. Open bar is control and filled bar is TGF-β
treated. *p < 0.05
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mediated attenuation of NOX4 and αSMA expression
during TGF-β treatment was efficiently restored by
AMPK knockdown (Fig. 2d).
NOX4 has been implicated as both an upstream and a
downstream mediator of TGF-β-mediated SMAD signal-
ing [8]. NOX4 knockdown attenuated phosphorylation
of SMAD2 and SMAD3 30 min after TGF-β treatment
(Fig. 3a). In line with the NOX4 knockdown experi-
ments, metformin significantly suppressed both SMAD2
and SMAD3 phosphorylation 30 min after TGF-β treat-
ment (Fig. 3b).
NOX4-mediated ROS production is responsible for TGF-β-
induced myofibroblast differentiation in LF
NOX4-mediated hydrogen peroxide (H2O2) production
of redox pathway modulation has been implicated in
regulating TGF-β signaling [8], hence intracellular ROS
production was examined by means of the CM-
H2DCFDA assay. TGF-β treatment induced ROS pro-
duction, which was significantly reduced by metformin
treatment (Fig. 4a). Knockdown experiments confirmed
that NOX4 is mainly responsible for TGF-β-induced
ROS production (Fig. 4b). No significant additional in-
hibition of ROS production was observed by metformin
treatment in NOX4 knockdown LF (Fig. 4b). Involvement
of TGF-β-induced ROS production in SMAD signaling
and myofibroblast differentiation was also examined by
using N-acetylcysteine (NAC), a representative intra-
cellular antioxidant. NAC treatment significantly sup-
pressed TGF-β-induced SMAD2/3 phosphorylation
and myofibroblast differentiation at the concentration
of 10 mM (Fig. 4c).
Metformin attenuates bleomycin-induced lung fibrosis
development in mice
Next, mouse models of BLM-induced lung fibrosis
were used to examine the anti-fibrotic action of met-
formin via NOX4 modulation. To show a possible
clinical relevance for metformin in treatment of IPF,
intraperitoneal metformin injection was initiated on
day 7 following BLM treatment. In general, day 7 is
considered to be the beginning of the fibrotic phase
with concomitant resolution of acute inflammatory re-
action. Compared with control treated mice, BLM
treated mice showed significant body weight loss,
which was markedly recovered during metformin
treatment (Fig. 5a). Metformin treatment clearly and
significantly reduced lung fibrosis development at day
Fig. 3 Metformin and NOX4 regulate SMAD phosphorylation in LF. a WB using anti-phospho-SMAD2, anti-SMAD2, anti-phospho-SMAD3, anti-
SMAD3, and anti-β-actin of cell lysates from control siRNA (lane 1, 2) and NOX4 siRNA (lane 3, 4) transfected LF. TGF-β (2 ng/ml) treatment was
started 48 h post transfection. Protein samples were collected after 30 min treatment with TGF-β. In the right panels are the average (±SEM) taken
from three independent experiments shown as relative expression. Open bar is control and filled bar is TGF-β treated. *p < 0.05. b WB using anti-
phospho-SMAD2, anti-SMAD2, anti-phospho-SMAD3, anti-SMAD3, and anti-β-actin of cell lysates from control (lane 1, 2) and metformin (10 mM)
(lane 3, 4) treated LF. Metformin treatment was started 1 h before TGF-β (2 ng/ml) stimulation and protein samples were collected after 30 min
treatment with TGF-β. In the right panels are the average (±SEM) taken from three independent experiments shown as relative expression. Open
bar is control and filled bar is TGF-β treated. *p < 0.05
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Fig. 4 (See legend on next page.)
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21 by means of Masson trichrome staining and Sircol
collagen assay, respectively (Fig. 5b, c).
To elucidate participation of TGF-β signaling through
the NOX4-SMAD axis in the BLM-induced lung fibrosis
and in attenuation of fibrosis by metformin, lung sam-
ples at day 21 were examined by immunohistochemistry.
Compared with control treated lungs, increased NOX4,
p-SMAD3, and αSMA expression were clearly observed
in fibrotic lesions in BLM-treated lungs (Fig. 5d). Con-
sistent with the results of in vitro experiments, metfor-
min clearly suppressed NOX4, p-SMAD3, and αSMA
expression levels in BLM-treated lungs (Fig. 5d). In line
with recent reports, clinical implications for NOX4 in
IPF pathogenesis for Japanese patients were further con-
firmed by showing positive NOX4 staining in FF fibro-
blasts (Fig. 5e). In comparison to LF from normal lungs,
LF isolated from IPF lungs also showed increased NOX4
expression levels (Fig. 5f ).
Discussion
In the present study, we demonstrate that metformin-
mediated AMPK activation is involved in the mecha-
nisms for attenuation of TGF-β-induced myofibroblast
differentiation in LF through inhibiting NOX4 expres-
sion (Fig. 6). Metformin regulates TGF-β-induced NOX4
expression at the mRNA level and NOX4 is responsible
for TGF-β-induced endogenous ROS production in LF.
Metformin treatment with concomitant NOX4 knock-
down indicates that NOX4 is mainly involved in the
mechanisms for metformin-mediated ROS inhibition
during TGF-β treatment (Fig. 4b). Metformin reduces
the expression levels of NOX4, SMAD phosphorylation,
and αSMA with concomitant attenuation of lung fibrosis
in BLM treatment, suggesting that the anti-fibrotic
mechanism of metformin is mainly attributable to inhib-
ition of TGF-β-mediated myofibroblast differentiation.
In line with recent findings, increased NOX4 expression
levels are also observed in FF fibroblasts of IPF lungs
and LF isolated from IPF lungs [10, 11]. Accordingly we
speculate that metformin regulation of NOX4 expression
can be a promising anti-fibrotic modality of treatment
for fibrotic lung disorders affected by TGF-β. Although re-
cent papers also showed an anti-fibrotic role for metfor-
min in BLM-induced lung fibrosis models [16], efficient
inhibition of BLM-induced lung fibrosis by metformin ad-
ministration during the fibrotic phase in the present
study further sheds light on the potential clinical use-
fulness of metformin for the treatment of IPF with
ongoing fibrotic process.
Metformin exhibits pleiotropic mechanisms for cell pro-
tection, mainly through AMPK activation. In addition to
energy metabolism, AMPK has been shown to be involved
in the regulation of various cellular processes, including
proliferation, mitochondrial integrity, inflammatory re-
sponse, ER stress, and oxidative stress [18]. AMPK activa-
tion is recognized to have potential beneficial effects not
only on improving metabolic disorders but also on pre-
venting organ dysfunction during fibrosis development,
including pulmonary diseases [23]. AMPK activation has
been implicated in metformin-mediated effectiveness
against a variety of lung pathologies, including lung cancer,
bronchial asthma, tuberculosis, cigarette smoke-induced
lung damages, ventilator-induced lung injury, and lipo-
polysaccharide (LPS)-induced lung injury [13, 15, 24–27].
Furthermore, a recent paper demonstrated that TGF-β-
induced myofibroblast differentiation and BLM-induced
lung fibrosis were efficiently suppressed by metformin-
mediated AMPK activation [16]. In our present study, we
have further elucidated that AMPK-mediated NOX4 sup-
pression in particular is involved in metformin’s anti-
fibrotic mechanisms.
NOX4 has been implicated as both an upstream and
downstream mediator in TGF-β signaling [8]. In line
with the NOX4 knockdown experiment, we showed that
metformin significantly suppressed SMAD phosphoryl-
ation (Fig. 3) and ROS production at 30 min after TGF-β
treatment (data not shown), suggesting that metformin-
mediated ROS suppressing mechanisms, including NOX4
regulation, may participate in the inhibition of SMAD
phosphorylation during TGF-β treatment. We have also
(See figure on previous page.)
Fig. 4 NOX4-mediated ROS is involved in the mechanisms for SMAD phospholylation and myofibroblast differentiation in LF. a Fluorescence
intensity of CM-H2DCFDA staining for intracellular ROS production. After 24 h treatment with TGF-β, incubation with CM-H2DCFDA (10 μM) was
performed for 30 min, fluorescence of DCF was measured by a fluorescence microplate reader. The fluorescence level in the control treated cells
in the absence of metformin was designated as 1.0. Shown panels are the average (±SEM) taken from three independent experiments. *p < 0.05.
b Fluorescence intensity of CM-H2DCFDA staining for intracellular ROS production. Metformin treatment was started 48 h post-siRNA transfection
and 1 h before TGF-β (2 ng/ml) stimulation. After 30 min incubation with CM-H2DCFDA, fluorescence of DCF was measured by a fluorescence
microplate reader. The fluorescence level in the control siRNA transfected cells without TGF-β and metformin treatment was designated as 1.0.
Shown panels are the average (±SEM) taken from six independent experiments. *p < 0.05. c WB using anti-phospho-SMAD2, anti-SMAD2, anti-
phospho-SMAD3, anti-SMAD3, anti-type I collagen, anti-αSMA, and anti-β-actin of cell lysates from control (lane 1, 2), NAC (1 mM) (lane 3, 4), and
NAC (10 mM) (lane 5, 6) treated LF. NAC treatment was started 1 h before TGF-β (2 ng/ml) stimulation and protein samples were collected after
24 h treatment for type I collagen and anti-αSMA WB, but 30 min for SMAD WB. Shown panels are the average (±SEM) taken from three
independent experiments shown as relative expression. Open bar is control and filled bar is TGF-β treated. *p < 0.05 and **p < 0.001
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treated LF with hydrogen peroxide (100 μM) in the pres-
ence or absence of TGF-β. However no effect on SMAD
phosphorylation was demonstrated by hydrogen peroxide
(data not shown), indicating not only the different
role between NOX4-mediated ROS and extrinsic ROS
but also permissive role of ROS in regulating cell sig-
naling by TGF-β. TGF-β-induced NOX4 expression is
also dependent on SMAD signaling, suggesting the
existence of a self-amplifying loop of TGF-β signaling
and NOX4 expression [8]. Intriguingly, recent papers
showed that NOX4 is essential for not only myofibroblast
differentiation but also subsequent phenotypic alterations
to apoptosis resistance by accelerating cellular senescence
in LF, which is associated with prolonged ECM production
during IPF pathogenesis [11, 28]. Along with regulation of
the myofibroblast phenotype in LF, NOX4 has also been
implicated in the regulation of TGF-β-induced apoptosis
in epithelial cells. In the case of NOX4 deficiency, due to
loss of intrinsic ROS generation, TGF-β failed to induce
apoptosis in alveolar epithelial cells (AEC) [10, 29]. In-
crease in NOX4 expression levels was observed not only
in LF of actively fibrosing areas but also injured epithelial
cells in IPF lungs [12, 28]. Hence, apoptosis inhibition in
AEC by NOX4 suppression can also be a beneficial part of
metformin treatment during IPF. siRNA-meditated NOX4
knockdown and low-molecular-weight NOX4 antagonist
have been shown to efficiently attenuate BLM-induced
lung fibrosis [12], further supporting the notion that
metformin-mediated NOX4 suppression can be a reason-
able and promising IPF treatment.
Due to the relative paucity of inflammatory cell infiltra-
tion as well as the failure of anti-inflammatory and im-
munosuppressive modality of treatments, the aberrant
wound healing process of excessive myofibroblast accu-
mulation has been recognized to be an essential pathology
for IPF development [30]. Recently available medical treat-
ments showing significant reduction in the rate of decline
of forced vital capacity are mainly mediated through anti-
fibrotic mechanisms [31, 32]. Furthermore, the majority of
ongoing clinical trials for IPF treatment are based on the
mechanisms of fibrogenesis, including TGF-β [6]. In gen-
eral, discovery and development of new drugs are a diffi-
cult and time-consuming process with unpredictable
adverse events. Drug repositioning is a recently proposed
new drug discovery strategy whereby a library of approved
drugs is screened for new indications [33]. The advantages
of drug repositioning are decreased risks for unexpected
adverse effects and simplified clinical trials. Metformin is
widely used for type II diabetes patients in clinical settings
with acceptable adverse events [34]. Hence, our findings
of an anti-fibrotic property of metformin indicate that
metformin can, through drug repositioning, be an al-
ternative approach for IPF treatment. In comparison
to clinically achievable plasma metformin concentra-
tions, we used higher concentrations of metformin in
in vitro experiments. Previous reports showing anti-
fibrotic and anti-inflammatory properties also selected
(See figure on previous page.)
Fig. 5 Effect of metformin on bleomycin-induced lung fibrosis development in mice. a Body Wight (BW) changes after BLM treatment. BW at day
0 before treatment was designated as 1.0. *p < 0.05. b Photomicrographs of Masson trichrome and Hematoxylin-Eosin staining of mouse lungs at
day 21. Upper panels are low magnification view of Masson trichrome staining. Original magnification × 40. Middle panels are High magnification
view of Masson trichrome staining. Original magnification × 100. Lower panels are high magnification view of Hematoxylin-Eosin staining. Original
magnification × 100. c Shown in the panel is the average (±SEM) soluble collagen measurement from Sircol assay using control (n = 13), BLM-
treated (n = 18), and BLM-treated with subsequent metformin injection mouse lungs (n = 15) at day 21. Open bar is control, filled bar is BLM-
treated, and horizontal crosshatched bar is BLM-treated with subsequent metformin injection. *p < 0.05. d Immunohistochemical staining of
NOX4, p-SMAD3, αSMA in mouse lungs at day 21. Upper panels are high magnification view of NOX4 staining. Original magnification × 200.
Middle panels are High magnification view of p-SMAD3 staining. Original magnification × 400. Lower panels are high magnification view of αSMA
staining. Original magnification × 200. Bar = 100 μm e Immunohistochemical staining of NOX4 in human lungs. Upper panels are high magnification
view of normal lungs. Original magnification × 200. Lower panels are High magnification view of IPF lungs. Original magnification × 400. Bar = 100 μm
f WB using anti-NOX4, and anti-β-actin of cell lysates from normal LF (lane 1, 2, 3) and IPF LF (lane 4, 5, 6). Lower panel is the average (±SEM) taken
from three patients shown as relative expression. Open bar is normal LF and filled bar is IPF LF. *p < 0.05
Fig. 6 Hypothetical model of metformin-mediated inhibition of
myofibroblast differentiation. Metformin-mediated AMPK activation
is responsible for inhibiting NOX4 expression and ROS production, which
is at least partly involved in the mechanisms for attenuation of TGF-β-
induced SMAD phosphorylation and myofibroblast differentiation in
relation to fibroblastic foci formation in IPF pathogenesis
Sato et al. Respiratory Research  (2016) 17:107 Page 10 of 12
similar concentrations of metformin as used in our
experiments [15, 16, 35], suggesting that a higher
concentration is necessary to see the efficacy in
in vitro conditions. However, mice were treated with
300 mg/kg of metformin, which is estimated to be
comparable to a metformin dose of around 1500 mg/
day for a 60 kg human [15]. Although we selected in-
traperitoneal administration in our mouse models,
bioavailability of oral administration of metformin is
calculated as 50 to 60 % in humans. Hence we specu-
late that the currently used maximum metformin dose
for diabetes treatment (2250 mg/day in Japan) might
be sufficient to see the anti-fibrotic properties of met-
formin treatment during IPF, which should be evalu-
ated in future studies.
Conclusions
In summary, we elucidated that metformin, an AMPK ac-
tivator, attenuates lung fibrosis development by inhibiting
TGF-β signaling through NOX4 suppression. We consider
metformin to be a promising candidate agent for an anti-
fibrotic modality of treatment for IPF patients.
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